Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:28:37.387Z.
Calculation as of: 2026-10-06T20:28:37.387Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e1fda49443de36a714599db7642de967ecff301c81a34b7e56bdc5d9ec4cb10a
PE RATIO
N/A
Market Cap
$29771.00
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6235.00
PE Ratio
N/A
TTM Avg
3571.19
3Y Avg
5980.81
5Y Avg
5980.81
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zhongchao Inc. (ZCMD) | $30389.00 | N/A | N/A | N/A | N/A |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $29771.00 | N/A | N/A | N/A | N/A |
| NewGenIvf Group Limited (NIVF)vs › | $6235.00 | N/A | 3571.19 | 5980.81 | 5980.81 |
| Akanda Corp. (AKAN)vs › | $61172.00 | N/A | N/A | N/A | N/A |
| PRF Technologies Ltd. (PRFX)vs › | $70884.00 | N/A | N/A | N/A | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $95475.00 | N/A | N/A | N/A | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $110112.00 | N/A | N/A | N/A | N/A |
| SciSparc Ltd. (SPRC)vs › | $250443.00 | N/A | N/A | N/A | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $378849.00 | N/A | N/A | N/A | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $403887.00 | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
